Rocket Pharmaceuticals, Inc. (RCKT) has a negative trailing P/E of -1.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 12.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -56.16%, forward earnings yield 8.14%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.8 | 0.10 | 2.23 | 0.00 | - |
| 2017 | -2.4 | 0.07 | 1.48 | 0.00 | - |
| 2018 | -7.8 | 0.14 | 3.01 | 0.00 | - |
| 2019 | -13.4 | 1.33 | 3.63 | 0.00 | - |
| 2020 | -20.7 | -0.43 | 6.03 | 0.00 | - |
| 2021 | -8.2 | -1.29 | 3.04 | 0.00 | - |
| 2022 | -6.0 | -0.28 | 2.72 | 0.00 | - |
| 2023 | -10.3 | 0.98 | 5.11 | 0.00 | - |
| 2024 | -4.6 | 0.71 | 2.57 | 0.00 | - |
| 2025 | -1.7 | 0.07 | 1.41 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-6.41 | $0.00 | $-42.85M | - |
| 2017 | $-4.36 | $0.00 | $-29.5M | - |
| 2018 | $-1.89 | $0.00 | $-74.52M | - |
| 2019 | $-1.70 | $0.00 | $-83.23M | - |
| 2020 | $-2.65 | $0.00 | $-146.67M | - |
| 2021 | $-2.68 | $0.00 | $-169.59M | - |
| 2022 | $-3.22 | $0.00 | $-219.38M | - |
| 2023 | $-2.92 | $0.00 | $-245.6M | - |
| 2024 | $-2.73 | $0.00 | $-258.75M | - |
| 2025 | $-2.01 | $0.00 | $-223.12M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.20 | $-1.39 – $-0.76 | $18.73M | $10.04M – $31.68M | 9 |
| 2027 | $-1.25 | $-1.84 – $-0.70 | $19.87M | $7.35M – $27.98M | 7 |
| 2028 | $-0.89 | $-1.46 – $0.72 | $78.87M | $33.51M – $118.44M | 6 |
| 2029 | $-0.51 | $-0.84 – $-0.13 | $177.62M | $75.45M – $266.74M | 4 |
| 2030 | $0.32 | $0.08 – $0.52 | $412.31M | $175.15M – $619.16M | 2 |
